
|Articles|October 8, 2020
QUIZ: The ALEX Study for ALK+ Non-Small Cell Lung Cancer
Author(s)Hannah Slater
In our lung cancer quiz, you’ll get to test your knowledge on the ALEX study.
Advertisement
What characteristics of alectinib therapy made it a viable treatment option versus crizotinib.
a. It has greater potency/selectivity for ALK.
b. It is a central nervous system penetrant.
c. It has the ability to target resistance mutations.
d. All of the above
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care
2
FDA Approves Niraparib Regimen in BRCA2+ Metastatic CSPC
3
How Should a Patient With Multiple Myeloma Manage Talquetamab’s Toxicity?
4
EMD Associated With Poorer Outcomes in Previously Treated R/R Multiple Myeloma
5















































































